THE EVALUATION OF THE EFFECTIVENESS AND SAFETY OF THE USE OF FIXED TRIPLE ORAL SUGAR-REDUCING THERAPY WITH DEBISTAL-GM IN PATIENTS WITH TYPE 2 DIABETES WITH OBESITY
Keywords:
type 2 diabetes mellitus, pioglitazone, fixed combination therapy for type 2 diabetes, triple antihyperglycemic therapyAbstract
Given the complexity and versatility of the pathogenesis of type 2 diabetes, the choice of
antihyperglycemic drugs is based on the importance of a simultaneous combined effect on several links in the pathogenesis of type 2 diabetes. The aim of the study was to study the hypoglycemic efficacy, clinical tolerance and safety of Debistal-GM in obese patients with type 2 diabetes. As a result of the study, high clinical efficacy, good tolerability and safety of Debistal-GM in obese type 2 diabetes were established. Inclusion criteria for the use of Debistal-GM are patients with type 2 diabetes with glycated hemoglobin values above 9%, but below 11%; with a diabetes duration of more than 5 years, with a body mass index of more than 30 kg / m 2.
References
Professional Practice Committee: Standards of Medical Care in Diabetes—2021/Diabetes Care .-2021 Jan; 44(Supplement 1).- S3-S3.
Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with
metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes ObesMetab. -2015;Vol. 17(3)-. p268-275.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular
outcomesintype 2 diabetes. N Eng J Med. -2016 Jul; Vol. 375(4).- p311-322.
Mkrtumyan A.M. Rezul'taty nablyudatel'nogo issledovaniya ESCALATION:
osobennosti primeneniya glimepirida u pacientov s saharnym diabetom 2-go tipa, ne dostigshih celevyh pokazatelej uglevodnogo obmena na fone terapii ingibitorom DPP-4 v kombinacii s metforminom [Results of the observational study ESCALATION: features of the use of glimepiride in patients with type 2 diabetes mellitus who did not achieve the goals of carbohydrate metabolism during therapy with a DPP-4 inhibitor in combination with metformin] //Problemy Endokrinologii. -2017;Tom 63(1)-. s30-38.
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I,
Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. -2009 Feb 7; Vol. 373(9662).- p473-81.
Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of
Early Glycemic Control on Future Complications (the Diabetes & Aging Study) Diabetes Care. -2019 March; Vol. 42(3).- p416-426.
Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular
events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-1289.
Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Thiazolidinediones improve beta-cell function
in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292(3):E871-883.
Wilcox R., Kupfer S., Erdmann E. PROactive Study Investigators. Effects of pioglitazone on
major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10) // Am. Heart J. 2008. Vol. 155. P. 712–717.
Massi-Benedetti M, Scheen A, Charbonnel B. Pioglitazone delays the need for permanent
insulin use: results from PROactive [abstract] Diabetes. 2006;55(Suppl 1):A124.
Scheen A, Charbonnel B. Reduced insulin requirements and improved glycaemic control
with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactive [abstract] Diabetes. 2006;55(Suppl 1):A134.
Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination
therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. -2007; Vol. 9(2).- p175-185.
Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment
satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. -2011; Vol. 27(6).- p1157-1168.
Morris A.D. Considerations in assessing effectiveness and costs of diabetes care: lessons
from DARTS // Diabetes Metab. Res. Rev. -2002; Vol. 18 (Suppl. 3). -S.32–35
